Ezharmia Tablet Post-marketing Surveillance

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT2031220503

Enrollment

150

Registered

2022-12-09

Start date

2022-12-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed or refractory Adult T-cell leukemia/lymphoma (ATL)

Interventions

none

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients who start receiving Ezharmia Tablet during the registration period.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Cumulative incidence of AEs (safety specifications of the survey and other AEs)	—

Contacts

Public ContactGPSP Contact

Daiichi Sankyo Co.,Ltd.

contact_gpsp@daiichisankyo.co.jp+81-362251059

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026